Literature DB >> 16513877

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.

Todd Lencz1, Delbert G Robinson, Ke Xu, Jenny Ekholm, Serge Sevy, Handan Gunduz-Bruce, Margaret G Woerner, John M Kane, David Goldman, Anil K Malhotra.   

Abstract

OBJECTIVE: All antipsychotics act on the dopamine D(2) receptor. The present study extends prior pharmacogenetic investigations of the D(2) receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region variation as a predictor of response time to two first-line atypical antipsychotics.
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine. Time until sustained response (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild types was examined by using Kaplan-Meier curves.
RESULTS: Relative to wild type homozygotes, G carriers (A-241G) exhibited a significantly faster time until response, whereas -141C Del carriers took a significantly longer time to respond. Diplotype analysis revealed similar results.
CONCLUSIONS: These findings suggest that variation in the D(2) receptor gene can, in part, explain variation in the timing of clinical response to antipsychotics in patients with first-episode schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513877     DOI: 10.1176/appi.ajp.163.3.529

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  54 in total

1.  Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?

Authors:  Juan A Gallego; Delbert G Robinson; Serge M Sevy; Barbara Napolitano; Joanne McCormack; Martin L Lesser; John M Kane
Journal:  J Clin Psychiatry       Date:  2011-09-06       Impact factor: 4.384

2.  PharmGKB summary: dopamine receptor D2.

Authors:  Huaiyu Mi; Paul D Thomas; Huijun Z Ring; Ruhong Jiang; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-06       Impact factor: 2.089

3.  Associations between DRDs and schizophrenia in a Korean population: multi-stage association analyses.

Authors:  Kyu Young Lee; Eun-Jeong Joo; Yong Ick Ji; Duk-Hwan Kim; Joo Bae Park; In-Won Chung; Sang Ick Lee; Yeon Ho Joo; Yong Min Ahn; Joo Yun Song; Yong Sik Kim
Journal:  Exp Mol Med       Date:  2011-01-31       Impact factor: 8.718

Review 4.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

5.  Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment.

Authors:  Ina Giegling; Antonio Drago; Martin Schäfer; Annette M Hartmann; Thomas Sander; Mohammad Reza Toliat; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Dan Rujescu; Alessandro Serretti
Journal:  Psychopharmacology (Berl)       Date:  2010-11-16       Impact factor: 4.530

6.  Pharmacogenetics of antipsychotic treatment response and side effects.

Authors:  B Mackenzie; Rp Souza; O Likhodi; Ak Tiwari; Cc Zai; J Sturgess; Dj Müller
Journal:  Therapy       Date:  2010-03

7.  Associations Between Dopamine D2 Receptor (DRD2) Gene, Maternal Positive Parenting and Trajectories of Depressive Symptoms from Early to Mid-Adolescence.

Authors:  Cong Cao; Jolien Rijlaarsdam; Anja van der Voort; Linqin Ji; Wenxin Zhang; Marian J Bakermans-Kranenburg
Journal:  J Abnorm Child Psychol       Date:  2018-02

Review 8.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

9.  Assessment of association between the dopamine D2 receptor (DRD2) polymorphism and neurodevelopment of children exposed to lead.

Authors:  Lian Liu; Xijin Xu; Taofeek Akangbe Yekeen; Kun Lin; Weiqiu Li; Xia Huo
Journal:  Environ Sci Pollut Res Int       Date:  2014-01-28       Impact factor: 4.223

10.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.